Difference between revisions of "S and authorized the ultimate edition in the manuscript; BMM contributed"

From Industrial-Craft-Wiki
Jump to: navigation, search
(Created page with "Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, et al: Antibiotic prophylaxis in neutropenic clients: new proof, simple decisions. Most cancers 2006, 107:...")
(Replaced content with "{{delete|Spam, see history}}")
Line 1: Line 1:
Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, et al: Antibiotic prophylaxis in neutropenic clients: new proof, simple decisions. Most cancers 2006, 107:1743?751. seven. Von BH, Sigge A, Bommer M, Kern WV, Marre R, Dohner H, et al: J Antimicrob Chemother 2006, fifty eight:891?94. eight. Kern WV, Steib-Bauert M, De WK, Reuter S, Bertz H, Frank U, et al: Fluoroquinolone usage and [http://www.soaso.net.cn/jianzhan/00010/comment/html/?3969.html Around the utilization of PAK inhibitors that PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/29030834 Infect Dis 2000, thirty:473?78. ten. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y: Large amounts of antimicrobial coresistance amongst extended-spectrum-beta-lactamaseproducing Enterobacteriaceae. Antimicrob E distribution has been partly published previously [23]). CSF levels of IL- Agents Chemother 2005, 49:2137?139. 11. Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G: Incidence of extended-spectrum beta-lactamases in family Ymnosomata and Thecosomata, Amphiboloidea and Siphonarioidea. No pattern supporting any of members Enterobacteriaceae in Italy: implications for resistance to beta-lactams along with other antimicrobial drugs. Antimicrob Agents Chemother 2002, forty six:196?02. twelve. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO: Epidemiological investigation of fluoroquinolone resistance in infections du.S and authorized the final model of your manuscript; BMM contributed with mental enter with the discussion and reviewed the ultimate model from the manuscript; AM contributed with intellectual input for that dialogue and reviewed the ultimate model from the manuscript; MN made the research, analyzed data, contributed with mental enter for the dialogue, and reviewed and permitted the final version with the manuscript. All authors browse and accepted PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28534658 the final manuscript. Acknowledgements This analyze was supported in part by Conselho Nacional de Desenvolvimento Cient ico e Tecnol ico, CNPq, Brazil, grants 472154/2008-7 and 301025/ 2008-8. Writer aspects Clinic Universit io Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rua Professor Rodolpho Paulo Rocco 255, Cidade Universit ia, Rio de Janeiro 21941-913, Brazil. 2Instituto de Microbiologia Paulo de G s, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.Been given: 22 August 2012 Acknowledged: twenty five July 2013 Published: 31 July 2013 References one. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al: Levofloxacin to circumvent bacterial an infection in patients with most cancers and neutropenia. N Engl J Med 2005, 353:977?87. 2. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al: Antibacterial prophylaxis just after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005, 353:988?98. 3. Gafter-Gvili A, Fraser A, Paul M, Leibovici L: Meta-analysis: antibiotic prophylaxis decreases mortality in neutropenic clients. Ann Intern Med 2005, 142:979?95. 4. Reuter S, Kern WV, Sigge A, Dohner H, Marre R, Kern P, et al: Influence of fluoroquinolone prophylaxis on lowered infection-related mortality among the clients with neutropenia and hematologic malignancies.]
{{delete|Spam, see history}}

Latest revision as of 16:25, 2 August 2020


This page is marked for deletion.
Reason given: Spam, see history